Our data demonstrated that the upregulation of transgelin in normal-phenotypic primary cells by TAGLN overexpression caused an increase in RAS and ERK1/2 activation, while the downregulation of transgelin in MPNST primary cells and cell lines by siRNA treatment resulted in decreased RAS and ERK1/2 activation (Fig. 3). This evidence concerns the gene MAPK3 and malignant peripheral nerve sheath tumor.